title: Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
abstract: OBJECTIVE
  To identify predictors and moderators of response to acute treatments among depressed adolescents (N = 439) randomly assigned to fluoxetine, cognitive-behavioral therapy (CBT), both fluoxetine and CBT, or clinical management with pill placebo in the Treatment for Adolescents With Depression Study (TADS).
  
  
  METHODS
  Potential baseline predictors and moderators were identified by a literature review. The outcome measure was a week 12 predicted score derived from the Children's Depression Rating Scale-Revised (CDRS-R). For each candidate moderator or predictor, a general linear model was conducted to examine main and interactive effects of treatment and the candidate variable on the CDRS-R predicted scores.
  
  
  RESULTS
  Adolescents who were younger, less chronically depressed, higher functioning, and less hopeless with less suicidal ideation, fewer melancholic features or comorbid diagnoses, and greater expectations for improvement were more likely to benefit acutely than their counterparts. Combined treatment, under no condition less effective than monotherapy, was more effective than fluoxetine for mild to moderate depression and for depression with high levels of cognitive distortion, but not for severe depression or depression with low levels of cognitive distortion. Adolescents from high-income families were as likely to benefit from CBT alone as from combined treatment.
  
  
  CONCLUSIONS
  Younger and less severely impaired adolescents are likely to respond better to acute treatment than older, more impaired, or multiply comorbid adolescents. Family income level, cognitive distortions, and severity of depression may help clinicians to choose among acute interventions, but combined treatment proved robust in the presence of moderators.
authors.affiliation: Duke Child and Family Study Center, NC 27705, USA. curry005@mc.duke.edu
authors.forename: John
authors.initials: J
authors.lastname: Curry
authors.forename: Paul
authors.initials: P
authors.lastname: Rohde
authors.forename: Anne
authors.initials: A
authors.lastname: Simons
authors.forename: Susan
authors.initials: S
authors.lastname: Silva
authors.forename: Benedetto
authors.initials: B
authors.lastname: Vitiello
authors.forename: Christopher
authors.initials: C
authors.lastname: Kratochvil
authors.forename: Mark
authors.initials: M
authors.lastname: Reinecke
authors.forename: Norah
authors.initials: N
authors.lastname: Feeny
authors.forename: Karen
authors.initials: K
authors.lastname: Wells
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Pathak
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Weller
authors.forename: David
authors.initials: D
authors.lastname: Rosenberg
authors.forename: Betsy
authors.initials: B
authors.lastname: Kennard
authors.forename: Michele
authors.initials: M
authors.lastname: Robins
authors.forename: Golda
authors.initials: G
authors.lastname: Ginsburg
authors.forename: John
authors.initials: J
authors.lastname: March
mesh_terms: D000293:Adolescent; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors